about
Adenine phosphoribosyltransferase deficiencyPhenotype and genotype characterization of adenine phosphoribosyltransferase deficiency18-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan, Côte d'Ivoire: a cohort study.Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review.Severe transient ADAMTS13 deficiency in pneumococcal-associated hemolytic uremic syndrome.Hemolytic uremic syndrome complicating Mycoplasma pneumoniae infection.Diagnosis of Streptococcus pneumoniae-associated hemolytic uremic syndrome.Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoringEffect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1.Primary hyperoxaluria.Epidemiology of chronic kidney disease in children.Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: phenotype-genotype correlation and outcome in 32 patients with CLDN16 or CLDN19 mutations.Defining left ventricular hypertrophy in children on peritoneal dialysis.The consequences of chronic kidney disease on bone metabolism and growth in children.Are there good reasons for inequalities in access to renal transplantation in children?Growth after renal transplantation.Maximizing growth in children after renal transplantation.Primary hyperoxaluria type 1: strategy for organ transplantation.2,8-Dihydroxyadenine urolithiasis: a not so rare inborn error of purine metabolism.Pathogens causing urinary tract infections in infants: a European overview by the ESCAPE study group.Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.Survival in children requiring chronic renal replacement therapy.Mortality risk disparities in children receiving chronic renal replacement therapy for the treatment of end-stage renal disease across Europe: an ESPN-ERA/EDTA registry analysis.Risk prediction models for graft failure in kidney transplantation: a systematic review.Racial variation in cardiovascular disease risk factors among European children on renal replacement therapy-results from the European Society of Paediatric Nephrology/European Renal Association - European Dialysis and Transplant Association RegistrChild-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.Age-Dependent Risk of Graft Failure in Young Kidney Transplant Recipients.Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome.Observations of a large Dent disease cohort.Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study.First report of rapidly progressive glomerulonephritis in tumor necrosis factor receptor-associated periodic syndrome.Microalbuminuria among HIV-infected antiretroviral therapy-naive children in the Democratic Republic of Congo.Advanced glycation end products in children with type 1 diabetes: family matters?Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome.
P50
Q28268826-8736B40F-617A-4055-83D0-427FFA7E241EQ28273050-CB219C2D-0EAB-4B25-8E7E-13C63A4724D9Q33336235-D3DED032-DA81-4CC8-8E9C-8F345F9ADF5EQ33390715-FA3E3473-BC49-4405-9F98-488703A47CCDQ33393302-1712033D-7E62-4E5D-BA12-FBC6834BFFEFQ33408648-0CB15F48-E09C-440A-84E5-0DB18CF290C4Q33410556-BA0997F4-DE90-4A89-8AAC-EBD55FBA6578Q34554467-4E6963D2-5FC9-4137-8EAC-D84834552662Q34658755-ABAF4EAE-4C1F-4189-8005-9DF769B6D908Q35073045-8E4AE388-D8C5-4660-876F-E8FB1F66D9E2Q35691019-BAE8FDBA-C4BA-42E4-B6DA-C33B49FF88D6Q35917451-04F37C33-9676-4759-BDDA-523BFD74C25CQ35985679-3F96B79E-C727-4FB9-B5CE-12121C071648Q36318290-F3ED320E-5596-47AE-AFD6-2CAE39F99069Q36801556-6023BCB3-AC6C-4D56-88E9-A05C204EA323Q37118565-8C980E8B-34D8-4B6B-9BB6-967568B311ECQ37661319-9F47B8A3-45F3-4C26-A897-3CA2E2994B8CQ37781989-BFC90876-40E4-4B9B-AEB5-4F6BB5A21150Q38221151-1FB5F443-AC36-4198-B097-22F7137C4AF8Q38271837-6B1B659C-1D84-4B34-965C-1C1038A56CE3Q38638596-2B88EB6C-D736-496E-A0E5-1B745293005AQ38784291-3C58335A-143C-4DC4-8AFC-734B67DBAA46Q38881512-A7EB4F90-393B-48D9-BB1E-144198D5D3E5Q38958123-413E5F7F-0659-41DF-B35E-5216E6AFC801Q38980491-EB77CE3F-5B36-4FF3-8D3A-4B339048B8D4Q39309115-FF90AFAD-DB15-4EB2-B184-5C133A869A20Q39534085-BF46DF80-6D40-49BD-A364-5775843CDF19Q39573394-9A3946C3-72E7-4424-B611-0FA9D4DEF179Q39656237-565ED566-1BBB-4D09-90AE-2133304910FCQ40169677-D3AF2F2B-C0ED-46B6-81AB-75743AE2C4ADQ40408589-12C82EE8-DFB6-4349-B7F0-C7407C58F71CQ40886517-08148A26-CC1E-42DE-8DF7-CAA74B77A7A4Q43019527-80F2811C-4381-4B08-9B81-11CCF1E998DBQ43218013-C63E7A42-BD02-4C69-8134-93C78D489EA0
P50
description
onderzoeker
@nl
name
Jérôme Harambat
@ast
Jérôme Harambat
@en
Jérôme Harambat
@es
Jérôme Harambat
@nl
Jérôme Harambat
@sl
type
label
Jérôme Harambat
@ast
Jérôme Harambat
@en
Jérôme Harambat
@es
Jérôme Harambat
@nl
Jérôme Harambat
@sl
prefLabel
Jérôme Harambat
@ast
Jérôme Harambat
@en
Jérôme Harambat
@es
Jérôme Harambat
@nl
Jérôme Harambat
@sl
P106
P21
P31
P569
2000-01-01T00:00:00Z